PIVOTAL EFFICACY STUDY OF INHIBITION OF GASTRIC ACID SECRETION BY PANTOPRAZOLE

泮托拉唑抑制胃酸分泌的关键功效研究

• 批准号: 6297819
• 负责人: JOSEPH R PISEGNA
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297819
• 关键词: Zollinger Ellison syndrome; antiulcer drug; benzimidazoles; clinical research; clinical trials; drug screening /evaluation; endocrine neoplasm; gastric acid; gastric juice inhibitor; gastrointestinal disorder chemotherapy; human subject; human therapy evaluation; intravenous administration; secretion; stomach surgery

The objective is to identify the regimens of intravenously (IV) administered pantoprazole that would decrease and maintain acid secretion at less than 10mEq/hr in patients with Zollinger-Ellison syndrome (ZES) with or without multiple endocrine neoplasia-type I (MEN- I) syndrome who have not undergone partial gastrectomy and at less than 5 mEq/hr in those patients with ZES with or without MEN-I who have undergone partial gastrectomy and to minor safety.

目的是确定静脉（IV）给药方案 给予泮托拉唑， 在Zollinger-Ellison患者中，分泌量低于10 mEq/hr 综合征（ZES）伴或不伴多发性内分泌肿瘤-I型（MEN- I）未接受胃部分切除术且小于 5 mEq/hr的ZES伴或不伴MEN-I患者， 接受了部分胃切除术，安全性较低。